Literature DB >> 11097200

Survey of hepatitis B and C in addiction treatment unit.

V P Dhopesh1, K R Taylor, W M Burke.   

Abstract

The survey on our unit revealed that 80% of injection drug users (IDUs) had hepatitis B core antibody (HBcAB), and 90% had hepatitis C virus antibody (HCVAB). Less than half of each group did not know or were unsure of the mode of transmission and spread of HCV. These findings emphasize the need to focus on education, especially about transmission of hepatitis B and C infection in drug addicts, particularly IDUs.

Entities:  

Mesh：

Year:  2000        PMID： 11097200     DOI： 10.1081/ada-100101903

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN： 0095-2990            Impact factor:   3.829


  18 in total

1.  Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations.

Authors:  Ann Drobnik; Caroline Judd; David Banach; Joseph Egger; Kevin Konty; Eric Rude
Journal:  Am J Public Health       Date:  2011-09-22       Impact factor: 9.308

2.  Missed opportunities for hepatitis C testing in opioid treatment programs.

Authors:  Jemima A Frimpong
Journal:  Am J Public Health       Date:  2013-04-18       Impact factor: 9.308

Review 3.  Barriers to hepatitis C treatment.

Authors:  Christopher E McGowan; Michael W Fried
Journal:  Liver Int       Date:  2012-02       Impact factor: 5.828

4.  Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users.

Authors:  Stephanie R Bialek; William A Bower; Karen Mottram; Dave Purchase; T Nakano; Omana Nainan; Ian T Williams; Beth P Bell
Journal:  J Urban Health       Date:  2005-07-27       Impact factor: 3.671

Review 5.  Epidemiology of HIV/AIDS, hepatitis B, hepatitis C, and tuberculosis among minority injection drug users.

Authors:  Antonio L Estrada
Journal:  Public Health Rep       Date:  2002       Impact factor: 2.792

6.  Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia.

Authors:  Trena I Mukherjee; Veena Pillai; Siti Hafizah Ali; Frederick L Altice; Adeeba Kamarulzaman; Jeffrey A Wickersham
Journal:  Int J Drug Policy       Date:  2017-06-23

7.  Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.

Authors:  Yi Zheng; Samuel Obeng; Huiqun Wang; Abdulmajeed M Jali; Bharath Peddibhotla; Dwight A Williams; Chuanchun Zou; David L Stevens; William L Dewey; Hamid I Akbarali; Dana E Selley; Yan Zhang
Journal:  J Med Chem       Date:  2019-01-11       Impact factor: 7.446

8.  A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care.

Authors:  Christopher E McGowan; Ali Monis; Bruce R Bacon; Josep Mallolas; Fernando L Goncales; Ioannis Goulis; Fred Poordad; Nezam Afdhal; Stefan Zeuzem; Teerha Piratvisuth; Patrick Marcellin; Michael W Fried
Journal:  Hepatology       Date:  2013-04       Impact factor: 17.425

Review 9.  Opioid dependence treatment: options in pharmacotherapy.

Authors:  Angela L Stotts; Carrie L Dodrill; Thomas R Kosten
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

10.  Pharmacological characterization of 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) as a dual selective MOR/KOR ligand with potential applications in treating opioid use disorder.

Authors:  Yi Zheng; Samuel Obeng; Bethany A Reinecke; Chongguang Chen; Palak S Phansalkar; David M Walentiny; Phillip M Gerk; Lee-Yuan Liu-Chen; Dana E Selley; Patrick M Beardsley; Yan Zhang
Journal:  Eur J Pharmacol       Date:  2019-11-16       Impact factor: 4.432
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.